UNSPSC 85819115: Transfusion of autologous white cells into peripheral artery, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to transfusion of autologous white cells into peripheral artery, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 30253Q0

UNSPSC 85819115 Transfusion of autologous white cells into peripheral artery, percutaneous approach is a Commodity code that shows no meaningful alignment with recent state and local procurement activity. The six most recent opportunities posted under or near this code — independent medical evaluations for public safety pension disability determinations (City of Phoenix Retirement Office), surgical procedure carve-out benefits for municipal employees (City of Long Beach), occupational medical surveillance for ferry workers (Washington State Department of Transportation), emergency and specialty medical services for detained youth (Harris County Juvenile Probation Department), pharmacy benefit management (Collier County Board of County Commissioners), and temporary health professional staffing pools (County of Santa Clara Health System) — involve municipal benefits administration, occupational health screening, youth detention healthcare, pharmacy claims processing, and temporary clinical staffing. None of these solicitations concern autologous white cell transfusions or vascular procedures. The code appears to be a highly specialized cellular immunotherapy code that does not map to what state and local governments are actually purchasing under it in current procurement.

Given the mismatch between the code's nominal scope and the actual work being solicited, this Commodity code represents minimal opportunity for business development focus. State and local procurement activity tagged to this code does not reflect purchases of autologous white cell transfusion services or the clinical infrastructure they require. If your firm offers services or products aligned with the code's true clinical scope, monitor this code for future activity, but current solicitation volume and relevance are negligible.